Merck is putting $338M into Korea as it bets on Asia growth. For $MRK this is incremental Asia exposure, and the signal matters more than the check size for the tape.

What happened: Merck opened a new production center in Daejeon, Korea, its largest life science investment in Asia-Pacific to date, as part of its "in-region, for-region" strategy. Key numbers: 300 million euros ($337 million) invested; about 300 jobs expected by 2028; Asia's share of the global innovative pipeline rose from 28 percent in 2020 to more than 40 percent; grant program provides products Why it matters: Merck aims to reduce reliance on US and European manufacturing sites and tap Asia's expanding biotech market, with possible additional production lines within one to five years.

Merck opened a new production center in Daejeon, Korea, its largest life science investment in Asia-Pacific to date, as part of its "in-region, for-region" strategy.

Merck aims to reduce reliance on US and European manufacturing sites and tap Asia's expanding biotech market, with possible additional production lines within one to five years.